Ser742
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser742  -  PRKD1 (human)

Site Information
GEksFRRsVVGtPAy   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448590
Available spectra:  4 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] ATP in vitro ( 73 ) , [32P] bio-synthetic labeling ( 98 ) , flow cytometry ( 4 ) , immunoassay ( 45 ) , immunoprecipitation ( 48 , 95 ) , mass spectrometry ( 5 , 7 , 8 , 10 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 46 , 47 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 58 , 59 , 60 , 61 , 62 , 63 , 65 , 66 , 69 , 70 , 71 , 72 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 83 , 84 , 86 ) , mutation of modification site ( 45 , 48 , 73 , 85 , 87 , 88 , 90 , 93 , 95 , 98 ) , phospho-antibody ( 3 , 4 , 45 , 48 , 57 , 64 , 67 , 68 , 73 , 81 , 82 , 85 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 ) , phosphopeptide mapping ( 98 ) , western blotting ( 3 , 4 , 45 , 48 , 57 , 64 , 67 , 68 , 81 , 85 , 87 , 88 , 89 , 90 , 92 , 93 , 94 , 95 , 96 , 97 , 99 )
Disease tissue studied:
breast cancer ( 35 , 45 , 96 ) , HER2 positive breast cancer ( 5 ) , luminal A breast cancer ( 5 ) , luminal B breast cancer ( 5 ) , breast cancer, surrounding tissue ( 5 ) , breast cancer, triple negative ( 5 ) , gastric cancer ( 32 ) , chronic lymphocytic leukemia ( 4 ) , liver cancer ( 57 ) , lung cancer ( 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 35 , 60 , 65 ) , non-small cell lung cancer ( 14 , 15 , 16 , 18 , 19 , 20 , 24 , 25 , 26 , 27 , 28 , 31 , 33 , 34 , 35 , 65 ) , non-small cell lung adenocarcinoma ( 14 , 15 , 16 , 17 , 18 , 19 , 20 , 26 , 28 ) , non-small cell large cell lung carcinoma ( 15 , 18 ) , non-small cell squamous cell lung carcinoma ( 17 , 34 ) , small-cell lung cancer ( 12 , 13 ) , neuroblastoma ( 30 ) , pancreatic cancer ( 64 , 99 ) , pancreatic carcinoma ( 64 , 99 ) , melanoma skin cancer ( 7 ) , rhabdomyosarcoma ( 67 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 68 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 61 ) , 293 (epithelial) ( 73 , 81 , 82 , 89 , 94 , 97 , 98 , 100 ) , 293E (epithelial) ( 49 ) , A431 (epithelial) [PRKD1 (human)] ( 88 ) , A498 (renal) ( 63 ) , A549 (pulmonary) ( 14 , 21 , 31 ) , B lymphocyte-blood ( 4 ) , B lymphocyte-spleen ( 89 ) , BAEC (endothelial) ( 91 ) , breast ( 5 ) , BT-20 (breast cell) ( 35 ) , BT-549 (breast cell) ( 35 ) , Cal-12T (pulmonary) ( 20 ) , Calu 6 (pulmonary) ( 35 ) , Calu-3 (pulmonary) ( 16 ) , CL1-0 (pulmonary) ( 60 ) , CL1-1 (pulmonary) ( 60 ) , CL1-2 (pulmonary) ( 60 ) , CL1-5 (pulmonary) ( 60 ) , COS (fibroblast) ( 85 , 88 , 98 ) , DMS153 (pulmonary) ( 19 ) , DMS53 (pulmonary) ( 13 ) , DMS79 (pulmonary) ( 12 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 36 ) , Flp-In T-Rex-293 (epithelial) ( 36 ) , H2009 (pulmonary) ( 35 ) , H2077 (pulmonary) ( 35 ) , H2887 (pulmonary) ( 35 ) , H322M (pulmonary) ( 35 ) , HCC1359 (pulmonary) ( 35 ) , HCC15 (pulmonary) ( 17 ) , HCC1937 (breast cell) ( 35 ) , HCC366 (pulmonary) ( 35 ) , HCC4006 (pulmonary) ( 35 ) , HCC44 (pulmonary) ( 20 ) , HCC78 (pulmonary) ( 18 , 35 ) , HCC827 (pulmonary) ( 16 , 35 ) , HCT116 (intestinal) ( 69 ) , HEK293T (epithelial) ( 48 ) , HeLa (cervical) ( 3 , 8 , 29 , 59 , 70 , 72 , 84 , 86 , 87 , 93 , 95 ) , HeLa S3 (cervical) ( 83 ) , HeLa_Meta (cervical) ( 62 ) , HeLa_Pro (cervical) ( 62 ) , HeLa_Telo (cervical) ( 62 ) , HOP62 (pulmonary) ( 35 ) , HUES-9 ('stem, embryonic') ( 58 ) , Huh7 (hepatic) ( 57 ) , HUVEC (endothelial) ( 90 , 91 ) , Jurkat (T lymphocyte) ( 22 , 39 , 40 , 41 , 42 , 46 , 47 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 66 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 92 ) , K562 (erythroid) ( 29 ) , LCLC-103H (pulmonary) ( 35 ) , LOU-NH91 (squamous) ( 17 , 35 ) , lung ( 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 65 ) , mast-bone marrow ( 89 ) , MCF-7 (breast cell) ( 35 , 45 ) , MDA-MB-231 (breast cell) ( 35 ) , MDA-MB-435 (breast cell) ( 96 ) , MDA-MB-435S (breast cell) ( 69 ) , MDA-MB-468 (breast cell) ( 35 ) , MDCK (epithelial) ( 45 ) , MKN-45 (gastric) ( 32 ) , MV4-11 (macrophage) ( 69 ) , myocyte-heart ( 48 , 73 ) , NB10 (neural crest) ( 30 ) , NCI-H128 (pulmonary) ( 12 ) , NCI-H1299 (pulmonary) ( 15 ) , NCI-H1355 (pulmonary) ( 14 ) , NCI-H1395 (pulmonary) ( 35 ) , NCI-H1417 (pulmonary) ( 12 ) , NCI-H1437 (pulmonary) ( 19 , 20 ) , NCI-H1568 (pulmonary) ( 35 ) , NCI-H1648 (pulmonary) ( 35 ) , NCI-H1650 (pulmonary) ( 16 ) , NCI-H1666 (pulmonary) ( 20 ) , NCI-H1703 (squamous) ( 17 , 34 ) , NCI-H1734 (pulmonary) ( 15 ) , NCI-H1781 (pulmonary) ( 18 ) , NCI-H1792 (pulmonary) ( 14 ) , NCI-H1944 (pulmonary) ( 15 ) , NCI-H1975 (pulmonary) ( 16 ) , NCI-H2030 (pulmonary) ( 35 ) , NCI-H2073 (pulmonary) ( 17 , 19 ) , NCI-H209 (pulmonary) ( 12 , 19 ) , NCI-H2106 (pulmonary) ( 16 ) , NCI-H2228 (pulmonary) ( 18 , 26 , 28 ) , NCI-H23 (pulmonary) ( 14 ) , NCI-H2342 (pulmonary) ( 17 ) , NCI-H2405 (pulmonary) ( 20 ) , NCI-H3122 (pulmonary) ( 18 , 24 , 25 , 27 ) , NCI-H322 (pulmonary) ( 35 ) , NCI-H3255 (pulmonary) ( 33 ) , NCI-H358 (pulmonary) ( 15 ) , NCI-H441 (pulmonary) ( 14 ) , NCI-H446 (pulmonary) ( 13 ) , NCI-H460 (pulmonary) ( 15 , 35 ) , NCI-H524 (pulmonary) ( 12 ) , NCI-H526 (pulmonary) ( 13 ) , NCI-H647 (pulmonary) ( 35 ) , NCI-H661 (pulmonary) ( 18 ) , NCI-H69 (pulmonary) ( 13 ) , NCI-H82 (pulmonary) ( 13 ) , NCI-H838 (pulmonary) ( 19 ) , NMuMG (epithelial) ( 45 ) , NPC (neural crest) ( 30 ) , PANC-1 (pancreatic) [PRKD1 (human), transfection] ( 64 ) , PANC-1 (pancreatic) ( 99 ) , PT-67 ( 90 ) , Rh13 (muscle cell) ( 67 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 10 ) , SKNDZ (neural crest) ( 88 ) , WM115 (melanocyte) ( 71 ) , WM239A (melanocyte) ( 7 )

Upstream Regulation
Regulatory protein:
Abl (human) ( 95 ) , AKAP13 (human) ( 81 ) , PKCD (human) ( 95 ) , PRKD1 (human) ( 64 ) , Src (human) ( 95 )
Putative in vivo kinases:
PKCA (human) ( 94 ) , PKCD (human) ( 95 ) , PKCH (human) ( 100 ) , PRKD1 (human) ( 73 , 85 ) , PRKD3 (human) ( 94 )
Kinases, in vitro:
PKCA (human) ( 98 ) , PKCD (human) ( 95 ) , PKCE (human) ( 95 ) , PKCH (human) ( 100 )
Treatments:
antibody ( 4 , 89 , 92 ) , arachidonic_acid ( 96 ) , ATP ( 73 ) , BAPTA-AM ( 90 ) , bisindolylmaleimide ( 99 ) , bombesin ( 85 ) , bradykinin ( 45 ) , BSO ( 95 ) , CID755673 ( 4 ) , colforsin ( 94 ) , DTBR ( 3 ) , EGF ( 45 , 86 ) , endothelin ( 48 , 81 ) , exercise ( 68 ) , fibronectin ( 82 ) , GF109203X ( 73 , 85 ) , Go_6976 ( 57 , 73 , 89 , 91 ) , Go_6983 ( 57 , 85 , 91 ) , H2O2 ( 87 , 91 , 93 , 95 ) , HB-EGF ( 63 ) , IBMX ( 94 ) , IGF-1 ( 67 ) , isoproterenol ( 48 ) , LPA ( 63 ) , neurotensin ( 64 , 99 ) , nocodazole ( 3 ) , norepinephrine ( 48 , 73 ) , PDGF ( 88 ) , phenylephrine ( 48 , 81 ) , phorbol_ester ( 45 , 48 , 67 , 73 , 88 , 94 , 95 , 97 , 98 , 99 , 100 ) , polyHEMA ( 82 ) , resveratrol ( 93 ) , RO-3306 ( 3 ) , Ro31-8220 ( 99 ) , salicylate ( 97 ) , STLC ( 3 ) , taxol ( 3 ) , TGF-beta ( 45 ) , thrombin ( 73 ) , TNF ( 91 ) , U73122 ( 90 ) , U73343 ( 90 ) , vanadate ( 88 , 95 ) , vasopressin ( 85 ) , VEGF ( 90 ) , virus infection ( 57 ) , wortmannin ( 67 , 89 )

Downstream Regulation
Effects of modification on PRKD1:
enzymatic activity, induced ( 57 , 85 , 91 , 95 , 98 ) , enzymatic activity, inhibited ( 73 ) , molecular association, regulation ( 91 , 93 , 98 ) , ubiquitination ( 3 )
Effects of modification on biological processes:
cell cycle regulation ( 3 ) , cell differentiation, altered ( 90 ) , cell growth, induced ( 3 ) , cell motility, altered ( 90 ) , signaling pathway regulation ( 3 ) , transcription, altered ( 95 )
Induce interaction with:
ASK1 (human) ( 91 ) , IKKB (human) ( 93 ) , JNK1 (human) ( 98 ) , PKCD (human) ( 93 )

References 

1

Chen X, et al. (2022) Identification of HPCAL1 as a specific autophagy receptor involved in ferroptosis. Autophagy, 1-21
35403545   Curated Info

2

Wang F, et al. (2022) Phosphorylation-dependent positive feedback on the oxytocin receptor through the kinase PKD1 contributes to long-term social memory. Sci Signal 15, eabd0033
35104164   Curated Info

3

Pangou E, et al. (2021) A PKD-MFF signaling axis couples mitochondrial fission to mitotic progression. Cell Rep 35, 109129
34010649   Curated Info

4

Saint-Georges S, et al. (2016) Protein kinase D-dependent CXCR4 down-regulation upon BCR triggering is linked to lymphadenopathy in chronic lymphocytic leukaemia. Oncotarget 7, 41031-41046
27127886   Curated Info

5

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

6

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

7

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

8

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

9

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

10

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

11

Döppler H, et al. (2014) Protein kinase d isoforms differentially modulate cofilin-driven directed cell migration. PLoS One 9, e98090
24840177   Curated Info

12

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

13

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

14

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

15

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

16

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

17

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

18

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

19

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

20

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

21

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

22

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

23

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

24

Rikova K (2013) CST Curation Set: 18531; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS*/T*) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759
Curated Info

25

Rikova K (2013) CST Curation Set: 18503; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966
Curated Info

26

Rikova K (2013) CST Curation Set: 18502; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966
Curated Info

27

Rikova K (2013) CST Curation Set: 18459; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

28

Rikova K (2013) CST Curation Set: 18458; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

29

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

30

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

31

Rikova K (2012) CST Curation Set: 16144; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]
Curated Info

32

Rikova K (2012) CST Curation Set: 16141; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

33

Rikova K (2012) CST Curation Set: 16142; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

34

Rikova K (2012) CST Curation Set: 16143; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

35

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

36

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

37

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

38

Rikova K (2012) CST Curation Set: 14275; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

39

Guo A (2012) CST Curation Set: 13981; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

40

Guo A (2012) CST Curation Set: 13982; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

41

Mulhern D (2012) CST Curation Set: 13829; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)
Curated Info

42

Mulhern D (2012) CST Curation Set: 13109; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

43

Rikova K (2012) CST Curation Set: 13733; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

44

Rikova K (2012) CST Curation Set: 13732; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 1/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

45

Bastea LI, Döppler H, Balogun B, Storz P (2012) Protein Kinase D1 Maintains the Epithelial Phenotype by Inducing a DNA-Bound, Inactive SNAI1 Transcriptional Repressor Complex. PLoS One 7, e30459
22276203   Curated Info

46

Mulhern D (2011) CST Curation Set: 13106; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

47

Mulhern D (2011) CST Curation Set: 13110; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -;
Curated Info

48

Phan D, Stratton MS, Huynh QK, McKinsey TA (2011) A novel protein kinase C target site in protein kinase D is phosphorylated in response to signals for cardiac hypertrophy. Biochem Biophys Res Commun 411, 335-41
21726532   Curated Info

49

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

50

Guo A (2011) CST Curation Set: 11886; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

51

Guo A (2011) CST Curation Set: 11887; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

52

Guo A (2011) CST Curation Set: 11888; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

53

Guo A (2011) CST Curation Set: 11890; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

54

Guo A (2011) CST Curation Set: 11891; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

55

Guo A (2011) CST Curation Set: 11892; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

56

Guo A (2011) CST Curation Set: 11893; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

57

Amako Y, Syed GH, Siddiqui A (2011) Protein Kinase D Negatively Regulates Hepatitis C Virus Secretion through Phosphorylation of Oxysterol-binding Protein and Ceramide Transfer Protein. J Biol Chem 286, 11265-74
21285358   Curated Info

58

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

59

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

60

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

61

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

62

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

63

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

64

Kisfalvi K, Hurd C, Guha S, Rozengurt E (2010) Induced overexpression of protein kinase D1 stimulates mitogenic signaling in human pancreatic carcinoma PANC-1 cells. J Cell Physiol 223, 309-16
20082306   Curated Info

65

Rikova K (2010) CST Curation Set: 9452; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

66

Possemato A (2010) CST Curation Set: 9349; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)Xp[ST](I/L/V)
Curated Info

67

Thimmaiah KN, Easton JB, Houghton PJ (2010) Protection from rapamycin-induced apoptosis by insulin-like growth factor-I is partially dependent on protein kinase C signaling. Cancer Res 70, 2000-9
20179209   Curated Info

68

McGee SL, Fairlie E, Garnham AP, Hargreaves M (2009) Exercise-induced histone modifications in human skeletal muscle. J Physiol 587, 5951-8
19884317   Curated Info

69

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

70

Chen Y, et al. (2009) Combined integrin phosphoproteomic analyses and small interfering RNA--based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res 69, 3713-20
19351860   Curated Info

71

Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115-31
19362540   Curated Info

72

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

73

Rybin VO, Guo J, Steinberg SF (2009) Protein kinase D1 autophosphorylation via distinct mechanisms at Ser744/Ser748 and Ser916. J Biol Chem 284, 2332-43
19029298   Curated Info

74

Zhou J (2009) CST Curation Set: 5901; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

75

Zhou J (2009) CST Curation Set: 5899; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

76

Zhou J (2009) CST Curation Set: 5900; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

77

Zhou J (2009) CST Curation Set: 5896; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

78

Zhou J (2009) CST Curation Set: 5898; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

79

Zhou J (2009) CST Curation Set: 5897; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

80

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

81

Carnegie GK, et al. (2008) AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway. Mol Cell 32, 169-79
18951085   Curated Info

82

Biliran H, et al. (2008) Protein kinase D is a positive regulator of Bit1 apoptotic function. J Biol Chem 283, 28029-37
18703509   Curated Info

83

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

84

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

85

Jacamo R, et al. (2008) Sequential protein kinase C (PKC)-dependent and PKC-independent protein kinase D catalytic activation via Gq-coupled receptors: differential regulation of activation loop Ser(744) and Ser(748) phosphorylation. J Biol Chem 283, 12877-87
18337243   Curated Info

86

Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51
18220336   Curated Info

87

Döppler H, Storz P (2007) A novel tyrosine phosphorylation site in protein kinase D contributes to oxidative stress-mediated activation. J Biol Chem 282, 31873-81
17804414   Curated Info

88

Johannessen M, et al. (2007) Protein kinase D induces transcription through direct phosphorylation of the cAMP-response element-binding protein. J Biol Chem 282, 14777-87
17389598   Curated Info

89

Lessmann E, et al. (2007) Oxysterol-binding protein-related protein (ORP) 9 is a PDK-2 substrate and regulates Akt phosphorylation. Cell Signal 19, 384-92
16962287   Curated Info

90

Qin L, Zeng H, Zhao D (2006) Requirement of protein kinase D tyrosine phosphorylation for VEGF-A165-induced angiogenesis through its interaction and regulation of phospholipase Cgamma phosphorylation. J Biol Chem 281, 32550-8
16891660   Curated Info

91

Zhang W, Zheng S, Storz P, Min W (2005) Protein kinase D specifically mediates apoptosis signal-regulating kinase 1-JNK signaling induced by H2O2 but not tumor necrosis factor. J Biol Chem 280, 19036-44
15755722   Curated Info

92

Chan SM, et al. (2004) Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med 10, 1390-6
15558056   Curated Info

93

Storz P, Döppler H, Toker A (2004) Activation loop phosphorylation controls protein kinase D-dependent activation of nuclear factor kappaB. Mol Pharmacol 66, 870-9
15226414   Curated Info

94

Carnegie GK, et al. (2004) AKAP-Lbc nucleates a protein kinase D activation scaffold. Mol Cell 15, 889-99
15383279   Curated Info

95

Storz P, Döppler H, Toker A (2004) Protein kinase Cdelta selectively regulates protein kinase D-dependent activation of NF-kappaB in oxidative stress signaling. Mol Cell Biol 24, 2614-26
15024053   Curated Info

96

Kennett SB, Roberts JD, Olden K (2004) Requirement of protein kinase C micro activation and calpain-mediated proteolysis for arachidonic acid-stimulated adhesion of MDA-MB-435 human mammary carcinoma cells to collagen type IV. J Biol Chem 279, 3300-7
14607845   Curated Info

97

Jiang G, et al. (2003) Salicylic acid reverses phorbol 12-myristate-13-acetate (PMA)- and tumor necrosis factor alpha (TNFalpha)-induced insulin receptor substrate 1 (IRS1) serine 307 phosphorylation and insulin resistance in human embryonic kidney 293 (HEK293) cells. J Biol Chem 278, 180-6
12409308   Curated Info

98

Hurd C, Waldron RT, Rozengurt E (2002) Protein kinase D complexes with C-Jun N-terminal kinase via activation loop phosphorylation and phosphorylates the C-Jun N-terminus. Oncogene 21, 2154-60
11948398   Curated Info

99

Guha S, Rey O, Rozengurt E (2002) Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res 62, 1632-40
11912133   Curated Info

100

Brändlin I, et al. (2002) Protein kinase C (PKC)eta-mediated PKC mu activation modulates ERK and JNK signal pathways. J Biol Chem 277, 6490-6
11741879   Curated Info